Afrocentric Investment (JSE:ACT) Debt-to-EBITDA : 0.97 (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Afrocentric Investment Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Afrocentric Investment's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was R186 Mil. Afrocentric Investment's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was R670 Mil. Afrocentric Investment's annualized EBITDA for the quarter that ended in Dec. 2023 was R884 Mil. Afrocentric Investment's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.97.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Afrocentric Investment's Debt-to-EBITDA or its related term are showing as below:

JSE:ACT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.02 Med: 0.57 Max: 1.15
Current: 1.01

During the past 13 years, the highest Debt-to-EBITDA Ratio of Afrocentric Investment was 1.15. The lowest was 0.02. And the median was 0.57.

JSE:ACT's Debt-to-EBITDA is ranked better than
69.46% of 429 companies
in the Healthcare Providers & Services industry
Industry Median: 2.57 vs JSE:ACT: 1.01

Afrocentric Investment Debt-to-EBITDA Historical Data

The historical data trend for Afrocentric Investment's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Afrocentric Investment Debt-to-EBITDA Chart

Afrocentric Investment Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-EBITDA

Get a 7-Day Free Trial

0.99

0.67

0.91

0.76

1.15

Afrocentric Investment Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															0.93	0.74	1.21	1.23	0.97

Competitive Comparison of Afrocentric Investment's Debt-to-EBITDA

For the Medical Care Facilities subindustry, Afrocentric Investment's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Afrocentric Investment's Debt-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Afrocentric Investment's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Afrocentric Investment's Debt-to-EBITDA falls into.

Afrocentric Investment Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Afrocentric Investment's Debt-to-EBITDA for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(291.651	+	704.688)	/	864.806
	=	1.15

Afrocentric Investment's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(185.896	+	669.532)	/	884.244
	=	0.97

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

Afrocentric Investment (JSE:ACT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Afrocentric Investment Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Afrocentric Investment's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Afrocentric Investment (JSE:ACT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Afrocentric Investment Corp Ltd (JSE:ACT) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

37 Conrad Road, Florida North, Roodepoort, ZAF, 1709

Website

http://www.afrocentric.za.com

Afrocentric Investment Corp Ltd is a black-owned investment holding company with an investment portfolio focused on services to the healthcare sector. It seeks to invest in healthcare-related businesses that demonstrate prospects for growth as well as diversify its revenue sources while contributing to the sustainable health and welfare of South African communities. The company provides health administration and health risk management solutions to the healthcare industry. It also provides a range of complementary services to its traditional medical scheme clients and a portfolio of healthcare-related enterprises. These services include information technology solutions, transactional switching, specialized disease management, pharmaceutical wholesaling, amongst others.